Philip A. Theodore, Senior Vice President, (843) 900-3211, [email protected] CNW Group 2015
Aeterna Zentaris Reports Third Quarter Financial and Operating Results
View original source (CNW)COSCIENS Biopharma Inc. on 6ix
Story so far
Earlier from COSCIENS Biopharma
- Aeterna Zentaris Announces Agreement to Exercise Substantially All Remaining Series B Warrants
- Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation
- Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results on November 6, 2015
- Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular
- Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
Later from COSCIENS Biopharma
- Aeterna Zentaris Urges Shareholders to Vote in Favor of the Share Consolidation and Highlights Support from ISS and Glass Lewis
- Aeterna Zentaris Announces Exercise of Series B Warrants
- Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
- Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
- Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD
Follow COSCIENS Biopharma into a list and get an email when it puts out news.
Follow COSCIENS Biopharma